Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin cost-effectiveness

This article was originally published in The Tan Sheet

Executive Summary

Increased use of aspirin for secondary prevention of coronary heart disease "is attractive from a cost-effectiveness perspective," while treatment with Rx clopidogrel "is currently unattractive" due to its high price, according to June 6 NEJM. Jean-Michel Gaspoz, MD, et al., Hopitaux Universitaires, Geneva, estimated incremental cost effectiveness from 2003-2007 of four strategies in CHD patients over 35. Researchers found extension of aspirin therapy from current levels of use to all eligible patients "would have an estimated cost-effectiveness ratio of about $11,000 per quality-adjusted year of life gained." Clopidogrel alone would have incremental cost of over $130,000, researchers say...
Advertisement

Related Content

Aspirin Demonstrates Cost Benefit Versus Statins In Heart Disease – Study

Topics

Advertisement
UsernamePublicRestriction

Register

PS094137

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel